Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSPT1 | P15170 | 2/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.33 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.31 |
| ▸ | WIZ | O95785 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27216591 | 0.86 | CRBN (0.49) | GSPT1DDB1CRBNCYP2C19KCNH2 | |
| SCHEMBL24880474 | 0.86 | CRBN (0.48) | GSPT1DDB1CRBNCYP2C19KCNH2 | |
| SCHEMBL24880604 | 0.78 | CRBN (0.47) | GSPT1DDB1CRBNCYP2C19KCNH2 | |
| SCHEMBL22557823 | 0.67 | CRBN (0.32) | GSPT1DDB1CRBNCYP2C19KCNH2 | |
| SCHEMBL27225820 | 0.67 | CRBN (0.35) | GSPT1DDB1CRBNCYP2C19KCNH2 | |
| SCHEMBL26106625 | 0.63 | WIZ (0.33) | GSPT1DDB1CRBNCYP2C19KCNH2 | |
| SCHEMBL28638497 | 0.62 | IKZF2 (0.66) | IKZF2 | |
| Hydrochloric Acid SCHEMBL27216595 | 0.62 | CRBN (0.46) | CRBNIKZF2 | |
| SCHEMBL19586581 | 0.61 | IKZF2 (0.37) | IKZF2 | |
| SCHEMBL19585407 | 0.61 | CRBN (0.41) | DDB1CRBNIKZF3IKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383908-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | HINOVA PHARMACEUTICALS INC. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4368614-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2024-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383908-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | DUSP1, PPM1D, PTPN1 | GSPT1 1672/4885DDB1 1687/4885CRBN 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.